Fig. 4: SRCi plus BRAFi promotes apoptosis and cell cycle arrest in BRAFm CRC cells.
From: Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer
Representative apoptotic profiles of Annexin V-APC/7-AAD staining of HT29 (a), WiDr (b), LS411N (c) and RKO (d) cell lines after the indicated treatments V (0.40, 1.50, 0.35, 1.85 (μM)), E (0.08, 2.00, 0.001, 2.00 (μM)), D (0.10, 0.03, 0.10, 0.10 (μM))) for 48 h. Below, histogram representation showing apoptotic rates. Mean and SD of 5 independent experiments are shown. Significance was considered for *P < 0.05, **P < 0.01, ***P < 0.001. Representative images of cell cycle distribution of HT29 (e), WiDr (f), LS411N (g) and RKO (h) cell lines after the indicated treatments (V (0.40, 0.10, 2.10, 1.85 (μM)), E (0.08, 0.30, 0.37, 0.60 (μM)), D (0.10, 0.02, 0.10, 0.10 (μM))) of one representative replicate are shown. Below, a bar diagram representation shows the percentage of G0/G1, S and G2 cells in each condition, showing mean ± SD of at least 3 biologically independent experiments. Asterisk above the bar means significance between that groups versus the control (DMSO), square brackets indicate it for the pointed groups. Significance is shown for S phase, considered for * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. NT non-treated, PI Propidium iodide, NT non-treated, V vemurafenib, E encorafenib, D dasatinib.
